既往非瓣膜性心房颤动合并急性心肌梗死患者住院期间抗栓治疗研究

doi:10.3969/j.issn.1673-5765.2017.02.006

摘要/Abstract

摘要：

目的回顾性调查既往非瓣膜性心房颤动（non-valvular atrial fibrillation，NVAF）合并急性心肌梗死（acute myocardial infarction，AMI）患者抗栓治疗实际应用情况，并分析住院期间双抗治疗（阿司匹林联合氯吡格雷或替格瑞洛）基础上肠外抗凝的抗栓疗效。方法纳入首都医科大学附属北京安贞医院2010年1月-2015年12月因AMI住院且出院诊断为AMI和 NVAF患者143例，其中NVAF病程≥1个月，统计抗栓治疗实际应用情况，将住院期间使用双抗治疗和肠外抗凝联合双抗治疗患者分为双抗组（33例）和三抗组（102例），比较两组间出血性事件[采用出血学术研究会（Bleeding Academic Research Consortium，BARC）出血定义]和缺血性事件（缺血性卒中、急性冠脉综合征再发和外周动脉栓塞）发生。结果 ①143例入选患者仅12.6%（18/143例）入院前使用华法林抗凝治疗。住院期间，71.3% （102/143例）患者使用肠外抗凝联合双抗，部分患者未使用任何抗凝治疗，双抗占23.1%（33/143 例），单抗（阿司匹林或氯吡格雷或替格瑞洛）占2.1%（3/143例）。患者出院带药中，超过2/3患者使用双抗治疗，比例占76.9%（103/134例），华法林联合双抗比例仅占4.5%（6/134例）。②住院期间双抗组相较于三抗组总出血性事件（BARC 2～5）、重大出血事件（BARC 3，5）和轻微出血事件（BARC 2）发生率低（3.0% vs 7.8%，0 vs 1.0%，3.0% vs 6.9%），而缺血性事件、缺血性卒中、外周动脉栓塞的发生率高（6.1% vs 3.9%，6.1% vs 1.0%，3.0% vs 0），但两组间差异均无显著性（P＞0.05）。结论本研究结果提示既往NVAF合并AMI患者住院期间部分患者未使用任何抗凝治疗，双抗基础上肠外抗凝治疗并未显著降低栓塞事件和增加出血事件，该类患者二级预防三重抗栓治疗比例很低。

文章导读： 本研究回顾性调查既往NVAF合并AMI患者住院期间和二级预防抗栓治疗实际应用情况，并分析住院期间双重抗血小板治疗基础上肠外抗凝的疗效，以期对该类患者抗栓治疗选择提供帮助。

关键词: 非瓣膜性心房颤动; 急性心肌梗死; 抗栓治疗; 三重抗栓治疗

Abstract:

Objective To investigate the application of antithrombotic therapy and analyze the effect of the antithrombotic treatment with parenteral anticoagulation and dual antiplatelet therapy (DT; aspirin+clopidogrel/ticagrelor) in hospitalized patients with acute myocardial infarction (AMI) and non-valvular atrial fibrillation (NVAF) retrospectively. Methods A total of 143 hospitalized patients who was admitted with AMI and diagnosed with NVAF within 1 month before admission between Jan 2010 and Dec 2015 in Department of Neurology of Beijing Anzhen Hospital were included in this study. The antithrombotic therapy information during hospitalization period and on discharge were investigated. Patients recevied DT during hospitalization period were divided into DT group (n =33) while patients recevied parenteral anticoagulation combined with DT were divided into TT group (triple antithrombotic therapy, n =102). The bleeding events according to the bleeding academic research criteria (BARC) and ischemic events (ie, ischemic stroke, recurrent acute coronary artery syndrome, peripheral arterial embolization) were compared between the two groups. Results ①Only 12.6% (18/143) of these 143 selected patients with NVAF were taking warfarin before their AMI admission. During hospitalization period, 71.3% (102/143) of those received parenteral anticoagulation combined with DT and there were some patients who didn’t receive any anticoagulant therapy, among which, DT accounted for 23.1% (33/143), and single antiplatelet therapy (ST; aspirin/clopidogrel/ticagrelor) accounted for 2.1% (3/143). On discharge, more than 2/3 patients received DT, accounting for 76.9% (103/134), and only 4.5% (6/134) received warfarin combined with DT. ②During hospitalization period, the rate of total bleeding events (BARC 2-5), major bleeding events (BARC 3, 5) and minor bleeding events (BARC 2) were lower (3.0% vs 7.8%, 0 vs 1.0%, 3.0% vs 6.9%), however, the rate of total ischemic events, ischemic stroke, peripheral arterial embolism rate were higher (6.1% vs 3.9%, 6.1% vs 1.0%, 3.0% vs 0) in DT group compared with TT group, while there was no significant difference between the two groups (P >0.05). Conclusion This study suggests that there are some patients who don’t received any anticoagulant therapy, and the parenteral anticoagulation combined with dual antiplatelet therapy does not significantly reduce the thrombotic events and increase the hemorrhagic events during hospitalization in patients with AMI and NVAF. What’s more, the proportion of the triple antithrombotic therapy as secondary prevention is very low in patients with AMI and NVAF.

Key words: Non-valvular atrial fibrillation; Acute myocardial infarction; Antithrombotic
therapy; Triple antithrombotic therapy

赵明磊，毕齐. 既往非瓣膜性心房颤动合并急性心肌梗死患者住院期间抗栓治疗研究[J]. 中国卒中杂志, 2017, 12(02): 124-130.

ZHAO Ming-Lei, BI Qi. Study on Antithrombotic Therapy of the Hospitalized Patients with Acute Myocardial Infarction and Non-valvular Atrial Fibrillation[J]. Chinese Journal of Stroke, 2017, 12(02): 124-130.

参考文献

1 Nabauer M，Ger th A，Limbourg T，et al. The

Registry of the German Competence NETwork on

Atrial Fibrillation：patient characteristics and initial

management[J]. Europace，2009，11：423-434.

2 Kralev S，Schneider K，Lang S，et al. Incidence and

severity of coronary artery disease in patients with

atrial fibrillation undergoing first-time coronary

angiography[J]. PLoS One，2011，6：e24964.

3 Wolf PA，Abbott RD，Kannel WB. Atrial fibrillation

as an independent r isk factor for st roke：the

Framingham study[J]. Stroke，1991，22：983-988.

4 Camm AJ，Lip GYH，de Caterina R，et al. 2012

focused update of the ESC Guidelines for the

management of atrial fibrillation：an update of the

2010 ESC guidelines for the management of atrial

fibrillation. Developed with the special contribution of

the European Heart Rhythm Association[J]. Eur Heart

J，2012，33：2719-2747.

5 Roff i M，Patrono C，Collet JP，et al. 2015 ESC

guidelines for the management of acute coronary

syndromes in patients presenting without persistent

ST-segment elevation[J]. Eur Heart J，2015，73：1207-

1294.

6 Task Force on the management of ST-segment

elevation acute myocardial infarction of the European

Society of Cardiology (ESC)，Steg PG，James SK，

et al. ESC guidelines for the management of acute

myocardial infarction in patients presenting with STsegment

elevation[J]. Eur Heart J，2012，33：2569-

2619.

7 杨柯君. 《抗血小板治疗中国专家共识》发表[J]. 上

海医药，2013，(14)：4.

8 张澍，杨艳敏，黄从新，等. 中国心房颤动患者卒中预

防规范[J]. 中华心律失常学杂志，2015，19：162-173.

9 Lip GY，Windecker S，Huber K，et al. Management

of antithrombotic therapy in atrial f ibrillation

patients presenting with acute coronary syndrome

and/or undergoing percutaneous coronary or valve

interventions：a joint consensus document of the

European Society of Cardiology Working Group on

Thrombosis，European Heart Rhythm Association

综上所述，既往NVAF合并AMI患者住院

期间部分患者未使用任何抗凝治疗，双抗基础

上肠外抗凝治疗并未显著降低栓塞事件和增加

出血事件，且该类患者二级预防大多数选择双

重抗血小板治疗，选择三重抗栓治疗比例很低。

130 Chin J Stroke, Feb 2017, Vol 12, No.2

(EHRA)，European Association of Percutaneous

Cardiovascular Interventions (EAPCI) and European

Association of Acute Cardiac Care (ACCA) endorsed

by the Heart Rhythm Society (HRS) and Asia-Pacific

Heart Rhythm Society(APHRS)[J]. Eur Heart J，2014，

35：3155-3179.

10 Mehran R，Rao SV，Bhatt DL，el at. Standardized

bleeding definitions for cardiovascular clinical trials：

a consensus report from the Bleeding Academic

Research Consortium[J]. Circulation，2011，123：

2736-2747.

11 Lip GY，Nieuwlaat R，Pisters R，et al. Refining

clinical risk stratification for predicting stroke and

thromboembolism in atrial fibrillation using a novel

risk factor-based approach：the Euro Heart Survey on

Atrial Fibrillation[J]. Chest，2010，137：263-272.

12 Pisters R，Lane DA，Nieuwlaat R，et al. A novel userfriendly

score (HAS-BLED) to assess 1-year risk of

major bleeding in patients with atrial fibrillation：the

Euro Heart Survey[J]. Chest，2010，138：1093-1100.

13 Lopes RD，Li L，Granger CB，et al. Atrial fibrillation

and acute myocardial infarction：antithrombotic

therapy and outcomes[J]. Am J Med，2012，125：897-

905.

14 Paikin JS，Wright DS，Eikelboom JW. Effectiveness

and safety of combined antiplatelet and anticoagulant

therapy：a critical review of the evidence from

randomized controlled trials[J]. Blood Rev，2011，25：

123-129.

15 吴昊，毕齐. 老年非瓣膜性心房颤动合并缺血性脑

血管病住院患者抗凝治疗研究[J].心肺血管病杂志，

2015，34：86-90.

[1]	郝先泽, 刘国庆, 姜英, 吴晓娟, 张小乔. 延髓“心”形梗死合并急性心肌梗死1例报道[J]. 中国卒中杂志, 2024, 19(3): 337-342.
[2]	杨佳洁, 张亮, 黄立安. 基于药物基因组学的急性缺血性卒中个体化抗栓治疗进展[J]. 中国卒中杂志, 2024, 19(10): 1111-1117.
[3]	姚浙吕，徐运. 脑微出血与卒中相关性研究进展[J]. 中国卒中杂志, 2020, 15(04): 365-370.
[4]	田成林. 脑微出血：共识、困惑与研究方向[J]. 中国卒中杂志, 2015, 10(10): 819-821.
[5]	代成波，王硕，段振鹏，曹裕民，张雄，王丽娟. 脑微出血对非腔隙性梗死抗栓治疗后早期出血转化的预测价值的初步研究[J]. 中国卒中杂志, 2013, 8(09): 712-717.
[6]	PRESS-China协作组. 缺血性卒中/TIA患者抗栓药物的使用及影响因素分析：中国七城市门诊连续病例的横断面调查[J]. , 2007, 2(04): 17-23.